Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, safety,
economic issues, dosage, and place in therapy of nebivolol are reviewed. Summary …

Objectives: Nebivolol is a selective β 1-adrenoceptor antagonist with endothelium-mediated
vasodilating properties. The effects of nebivolol on renal haemodyamics are unknown in …

Background Nebivolol represents a new therapeutic class of beta blockers with high beta1
selectivity and the ability to modu late the direct vascular reactions through the liberation of …

Nebivolol is a third generation β-blocker. It is highly selective for the β1-adrenoceptor, and
has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

Objective (s): Despite several proposed mechanisms for the pathophysiology of cardiorenal
syndrome (CRS), the exact mechanism remains unclear. Nitrosative stress has been argued …

Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …

New evidence from recently completed clinical studies performed with nebivolol, a highly
selective beta‐1 β‐blocker, endowed with additional vasodilating activity mediated by nitric …

Nebivolol is known as a highly selective β1-adrenoceptor antagonist. Based on the reported
vasodilator effect of nebivolol, we examined the cellular mechanisms by which the drug …

Abstract β-Adrenoceptor antagonists (β-blockers) have historically been considered an
effective and safe option for first-line treatment of hypertension. However, very recently, it …